Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer

Cui, Xiangrong; Xuan, Jianhua; Yi, Qiu; Chen, Long; Tan, Bin; Li, Xin; Chen, Xueni; Huang, Yue; Xiang, Zhongping; Tian, Jie; Zhu, Jing

doi:10.18632/oncotarget.23226

Cited by 20 publications

(15 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…STAT3 signaling is frequently activated in malignant cells and mediates tumor cell proliferation, invasion, survival, and inflammation by promoting nuclear factor‐κB (NF‐κB) and IL‐6‐gp130–JAK cascades (Yu, Pardoll, & Jove, 2009). STAT3 overexpression has been observed in lung, ovarian, gastric, blood, and brain cancers (Cui et al, 2018). So that in head and neck and also in epidermoid (A431) tumor cell lines targeting STAT3 using small hairpin RNA results in reduced growth compared with control (Luwor et al, 2013).…”

Section: The Role Of Jak/stat Signaling Pathway In Cancers and Autoimmentioning

confidence: 99%

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Hosseini

Gharibi

Marofi

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK-STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small-molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune-mediated diseases. K E Y W O R D S autoimmune diseases, cancer, Janus kinase inhibitors, novel treatment strategy

show abstract

Section: The Role Of Jak/stat Signaling Pathway In Cancers and Autoimmentioning

confidence: 99%

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Hosseini

Gharibi

Marofi

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Cancer progression is a series of histopathological process, which is influenced by somatically acquired genetic, epigenetic, transcriptomic and proteomic alterations [65][66][67]. Somatic loss-of-function or gain-of-function alterations ensue in particular genomic regions which engaged in potential inhibitory or carcinogenic effects, respectively [68,69]. Therefore, we exploited the cBioPortal web tool to exhibit the Copy Number Alterations, mutations and mutant mRNA expressions.…”

Section: Discussionmentioning

confidence: 99%

A Multi-Omics Analysis of Bone Morphogenetic Protein 5 (BMP5) mRNA Expression and Clinical Prognostic Outcomes in Different Cancers Using Bioinformatics Approaches

Karim¹,

Samad²,

Adhikari

et al. 2020

Biomedicines

View full text Add to dashboard Cite

Cumulative studies have provided controversial evidence for the prognostic values of bone morphogenetic protein 5 (BMP5) in different types of cancers such as colon, breast, lung, bladder, and ovarian cancer. To address the inconsistent correlation of BMP5 expression with patient survival and molecular function of BMP5 in relation to cancer progression, we performed a systematic study to determine whether BMP5 could be used as a prognostic marker in human cancers. BMP5 expression and prognostic values were assessed using different bioinformatics tools such as ONCOMINE, GENT, TCGA, GEPIA, UALCAN, PrognoScan, PROGgene V2 server, and Kaplan–Meier Plotter. In addition, we used cBioPortal database for the identification and analysis of BMP5 mutations, copy number alterations, altered expression, and protein–protein interaction (PPI). We found that BMP5 is frequently down-regulated in our queried cancer types. Use of prognostic analysis showed negative association of BMP5 down-regulation with four types of cancer except for ovarian cancer. The highest mutation was found in the R321*/Q amino acid of BMP5 corresponding to colorectal and breast cancer whereas the alteration frequency was higher in lung squamous carcinoma datasets (>4%). In PPI analysis, we found 31 protein partners of BMP5, among which 11 showed significant co-expression (p-value < 0.001, log odds ratio > 1). Pathway analysis of differentially co-expressed genes with BMP5 in breast, lung, colon, bladder and ovarian cancers revealed the BMP5-correlated pathways. Collectively, this data-driven study demonstrates the correlation of BMP5 expression with patient survival and identifies the involvement of BMP5 pathways that may serve as targets of a novel biomarker for various types of cancers in human.

show abstract

“…It is primarily influenced by four major factors -somatically acquired genetic, epigenetic, transcriptomic, and proteomic alterations [91,92]. Somatic loss-of-function or gain-of-function alterations occur in particular genomic regions involved in potential inhibitory or carcinogenic effects, respectively [93,94]. Therefore, we used cBioPortal to determine human cancers with CNAs and mutations in prominin genes.…”

Section: Discussionmentioning

confidence: 99%

PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis

et al. 2019

View full text Add to dashboard Cite

Prominin 1 (PROM1) is considered a biomarker for cancer stem cells, although its biological role is unclear. Prominin 2 (PROM2) has also been associated with certain cancers. However, the prognostic value of PROM1 and PROM2 in cancer is controversial. Here, we performed a systematic data analysis to examine whether prominins can function as prognostic markers in human cancers. The expression of prominins was assessed and their prognostic value in human cancers was determined using univariate and multivariate survival analyses, via various online platforms. We selected a group of prominent functional protein partners of prominins by protein-protein interaction analysis. Subsequently, we investigated the relationship between mutations and copy number alterations in prominin genes and various types of cancers. Furthermore, we identified genes that correlated with PROM1 and PROM2 in certain cancers, based on their levels of expression. Gene ontology and pathway analyses were performed to assess the effect of these correlated genes on various cancers. We observed that PROM1 was frequently overexpressed in esophageal, liver, and ovarian cancers and its expression was negatively associated with prognosis, whereas PROM2 overexpression was associated with poor overall survival in lung and ovarian cancers. Based on the varying characteristics of prominins, we conclude that PROM1 and PROM2 expression differentially modulates the clinical outcomes of cancers.

show abstract

Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer

Cited by 20 publications

References 57 publications

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

A Multi-Omics Analysis of Bone Morphogenetic Protein 5 (BMP5) mRNA Expression and Clinical Prognostic Outcomes in Different Cancers Using Bioinformatics Approaches

PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis

Contact Info

Product

Resources

About